两分次立体定向消融放疗(SABR)与两分次高剂量率(HDR)近距离放疗治疗局限性前列腺癌:剂量不均匀性是否重要?
该平行队列分析比较两分次前列腺SABR与两分次HDR单药治疗两项前瞻性II期试验,纳入30例SABR和83例HDR患者。两组72个月累积生化失败概率分别为3.5%和12.8%(p=0.19),急性和晚期毒性及生活质量无差异。作者认为两分次SABR与两分次HDR近距离放疗的生化失败率、毒性和生活质量相似,支持设计随机对照试验。
要点
- 两分次SABR与两分次HDR单药治疗的72个月累积生化失败概率分别为3.5%和12.8%(p=0.19)。
- 两组中位PSA最低值均为0.16 ng/mL,中位达最低值时间为治疗后57个月。
- 两组CTCAE≥2级毒性发生率均低,EPIC评分随时间无组间差异。
核心结论
- 两分次SABR与两分次HDR近距离放疗的生化失败率、急性和晚期毒性及生活质量相似,作者认为这些数据支持设计比较这两种治疗的随机对照试验。
研究设计与样本
- 平行队列分析,比较两项前瞻性II期临床试验中两分次前列腺SABR与两分次HDR单药治疗。
- 纳入组织学确诊前列腺癌患者,临床分期T1c-T2b、分级组1、2或3、PSA<20 ng/mL。
- SABR剂量为26 Gy分2次每周照射,HDR剂量为27 Gy分2次每周照射。
- 纳入分析SABR组30例、HDR组83例;SABR组和HDR组分别有50%和30%患者为不利中间风险疾病。
主要发现
- SABR组基线平均PSA为8.7 ng/mL,HDR组为6.8 ng/mL(p=0.016)。
- SABR组和HDR组中位随访时间分别为72.7个月和65.3个月。
- SABR组平均交付剂量(Dmean)为26.6-26.8 Gy,HDR组为35.5-45.5 Gy。
- 两组中位PSA最低值均为0.16 ng/mL,中位达最低值时间为治疗后57个月。
- 72个月累积生化失败概率(±SE)SABR组为3.5%(±3.5%),HDR组为12.8%(±4.8%)(p=0.19)。
关键数值与推荐
- 两组CTCAE≥2级毒性发生率均低,EPIC评分随时间无组间差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Contemporary radiotherapy for localized prostate cancer (PCa) is deliverable via stereotactic ablative radiotherapy (SABR) and high dose rate (HDR) brachytherapy. Here we report on a parallel cohort analysis of two prospective, phase II clinical trials of two-fraction prostate SABR versus two-fraction HDR monotherapy. MATERIALS AND METHODS: Enrolled patients had histologically-confirmed PCa (clinical stage T1c-T2b; grade group 1, 2, or 3; and PSA < 20 ng/mL). SABR and HDR doses were 26 Gy and 27 Gy in 2 weekly fractions, respectively. Patient-level data from each cohort was analysed to assess prostate specific antigen (PSA) response kinetics, biochemical failure, toxicity, and quality of life (QOL). RESULTS: Thirty patients receiving SABR and 83 receiving HDR were included. Fifty percent and 30% of patients had unfavourable-intermediate risk disease, respectively. SABR patients had higher mean baseline PSA (8.7 versus 6.8 ng/mL, p = 0.016). Median follow-up was 72.7 and 65.3 months, respectively. Mean dose delivered (Dmean) was 26.6-26.8 Gy for SABR versus 35.5-45.5 Gy for HDR. Both cohorts achieved a median nadir PSA of 0.16 ng/mL at a median of 57 months post-treatment. Cumulative biochemical failure probability (±SE) at 72 months was 3.5% (±3.5%) for SABR versus 12.8% (±4.8%) for HDR (p = 0.19). Low rates of CTCAE grade ≥2 toxicity were observed in both cohorts. No differences in EPIC scores over time were observed between cohorts. CONCLUSIONS: Two-fraction SABR yields similar rates of biochemical failure, acute and late toxicities, and QOL as two-faction HDR brachytherapy. These data support the design of a randomized controlled trial comparing these treatments.
引用
- Correa RJM, Morton G, Chung HT, et al. Two-fraction stereotactic ablative radiotherapy (SABR) versus two-fraction high dose rate (HDR) brachytherapy for localized prostate cancer: Does dose heterogeneity matter? Radiother Oncol. 2022. PMID: 35151715. doi:10.1016/j.radonc.2022.02.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。